Scilex (NASDAQ:SCLX – Get Free Report) is one of 284 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Scilex to related companies based on the strength of its valuation, institutional ownership, dividends, earnings, analyst recommendations, risk and profitability.
Earnings and Valuation
This table compares Scilex and its rivals revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Scilex | $46.74 million | -$114.33 million | -1.03 |
Scilex Competitors | $564.51 million | -$29.75 million | 6.81 |
Scilex’s rivals have higher revenue and earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Insider and Institutional Ownership
69.7% of Scilex shares are owned by institutional investors. Comparatively, 50.6% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 8.7% of Scilex shares are owned by insiders. Comparatively, 16.2% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Scilex and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Scilex | -244.60% | N/A | -112.17% |
Scilex Competitors | -4,555.97% | -209.87% | -46.37% |
Analyst Recommendations
This is a summary of current ratings and price targets for Scilex and its rivals, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Scilex | 0 | 0 | 2 | 0 | 3.00 |
Scilex Competitors | 1431 | 4412 | 11731 | 204 | 2.60 |
Scilex presently has a consensus target price of $8.00, suggesting a potential upside of 501.50%. As a group, “Biological products, except diagnostic” companies have a potential upside of 113.46%. Given Scilex’s stronger consensus rating and higher probable upside, analysts plainly believe Scilex is more favorable than its rivals.
Summary
Scilex rivals beat Scilex on 7 of the 13 factors compared.
About Scilex
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.
Receive News & Ratings for Scilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scilex and related companies with MarketBeat.com's FREE daily email newsletter.